Home > Insider Trading > Filing (0001178913-22-002093)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1534248	Chemomab Therapeutics Ltd.	CMMB	Pharmaceutical Preparations (2834)	813676773

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1840006	Harris Neil Cohen	C/O Chemomab Therapeutics Ltd., 1 Kendall Sq, Bldg 1400E, Ste 14-105 Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
American Depositary Shares	Acquisiton	2022-05-18	2,000	$3.19	12,409	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
American Depositary Shares	Option to Purchase American Depositary Shares	Acquisiton	2022-03-07	6,820	$0.00	6,820	$3.53
American Depositary Shares	Option to Purchase American Depositary Shares	Acquisiton	2021-04-19	11,884	$0.00	11,884	$27.26
American Depositary Shares	Option to Purchase American Depositary Shares	Acquisiton	2021-03-16	688	$0.00	688	$13.17

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
6,820	2032-03-07	No	4	A	Direct
11,884	2031-04-19	No	4	A	Direct
688	2030-07-15	No	4	A	Direct

Footnotes

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
Includes the previously reported 10,409 ADSs of the Company, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on March 15, 2022.
No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
These options vest and become exercisable in their entirety on March 16, 2023 subject to the Reporting Person's continued service.
These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
These options vest and become exercisable as follows: 1/3 vested on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.